Citadel Advisors’s Genomic Health, Inc. GHDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-6,100
| Closed | -$414K | – | 10196 |
|
|
2019
Q3 | $414K | Sell |
6,100
-700
| -10% | -$48.1K | ﹤0.01% | 7077 |
|
|
2019
Q2 | $396K | Sell |
6,800
-700
| -9% | -$41.5K | ﹤0.01% | 7166 |
|
|
2019
Q1 | $525K | Buy |
7,500
+1,800
| +32% | +$133K | ﹤0.01% | 6712 |
|
|
2018
Q4 | $367K | Sell |
5,700
-7,200
| -56% | -$505K | ﹤0.01% | 6919 |
|
|
2018
Q3 | $906K | Buy |
12,900
+600
| +5% | +$35.1K | ﹤0.01% | 5717 |
|
|
2018
Q2 | $620K | Buy |
+12,300
| New | +$488K | ﹤0.01% | 6021 |
|
|
2016
Q1 | – | Sell |
-1,900
| Closed | -$67K | – | 8562 |
|
|
2015
Q4 | $67K | Sell |
1,900
-1,800
| -49% | -$48.2K | ﹤0.01% | 7072 |
|
|
2015
Q3 | $78K | Buy |
3,700
+700
| +23% | +$18K | ﹤0.01% | 7205 |
|
|
2015
Q2 | $83K | Buy |
3,000
+1,000
| +50% | +$28.2K | ﹤0.01% | 7276 |
|
|
2015
Q1 | $61K | Buy |
2,000
+1,200
| +150% | +$38.1K | ﹤0.01% | 7256 |
|
|
2014
Q4 | $26K | Sell |
800
-1,800
| -69% | -$58.6K | ﹤0.01% | 7633 |
|
|
2014
Q3 | $74K | Buy |
2,600
+800
| +44% | +$22.3K | ﹤0.01% | 6646 |
|
|
2014
Q2 | $49K | Sell |
1,800
-1,700
| -49% | -$45.2K | ﹤0.01% | 6755 |
|
|
2014
Q1 | $92K | Buy |
3,500
+1,300
| +59% | +$37.3K | ﹤0.01% | 6279 |
|
|
2013
Q4 | $64K | Sell |
2,200
-1,400
| -39% | -$44.4K | ﹤0.01% | 5904 |
|
|
2013
Q3 | $110K | Sell |
3,600
-13,800
| -79% | -$462K | ﹤0.01% | 5289 |
|
|
2013
Q2 | $552K | Buy |
+17,400
| New | +$571K | ﹤0.01% | 3752 |
|
Citadel Advisors's GHDX Position: Q3 2019 in Review
Citadel Advisors sold out of Genomic Health, Inc. (GHDX) in Q3 2019, closing a stake of 291,969 shares — an estimated $20.1M sold.
Citadel Advisors first reported a position in GHDX in Q2 2013 and held it in 24 quarters. The position peaked at $24.9M in Q1 2019. 221 funds tracked by Wall St. Rank hold GHDX as of Q3 2019.
- Citadel Advisors reported no remaining Genomic Health, Inc. position as of Q3 2019 after selling out during the quarter.
- Citadel Advisors sold 291,969 Genomic Health, Inc. shares in Q3 2019, an estimated $20.1M.
- Citadel Advisors first reported a position in Genomic Health, Inc. in Q2 2013 and held it in 24 quarters.
- Citadel Advisors's Genomic Health, Inc. position peaked at $24.9M in Q1 2019.
- 221 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q3 2019.
Based on Citadel Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.